Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Tolerion General Information
Tolerion has developed a novel antigen-specific immune tolerance induction platform to address the root causes of autoimmune diseases. Its lead candidate, TOL‑3021—a tolerizing biologic for type 1 diabetes—has completed a Phase 2 study showing significant improvement in C-peptide levels versus placebo. This biomarker indicates improved pancreatic insulin production and beta cell mass. No disease-modifying drugs currently exist for type 1 diabetes, making this a potentially first-in-class therapy with large market potential. Other pipeline assets target multiple sclerosis and myasthenia gravis; the MS program was discontinued while myasthenia gravis remains pending.[5][2][4]
Contact Information
Primary Industry
Biotech
Corporate Office
South San Francisco, California
United States
United States
Drug Pipeline
BHT-3009
Phase 2Key Partnerships
Tolerion Funding
No funding data available
To view Tolerion's complete valuation and funding history, request access »